The potential similarities of COVID-19 and autoimmune disease pathogenesis and therapeutic options: new insights approach
Abstract Cytokine pathways and their signaling disorders can be the cause of onset and pathogenesis of many diseases such as autoimmune diseases and COVID-19 infection. Autoimmune patients may be at higher risk of developing infection due to the impaired immune responses, the use of immunosuppressive drugs, and damage to various organs. Increased secretion of inflammatory cytokines and intolerance of the patient’s immune system to COVID-19 infection are the leading causes of hospitalization of these patients. The content used in this paper has been taken from English language articles (2005–2020) retrieved from the PubMed database and Google Scholar search engine using “COVID-19,” “Autoimmune disease,” “Therapeutic,” “Pathogenesis,” and “Pathway” keywords. The emergence of COVID-19 and its association with autoimmune disorders is a major challenge in the management of these diseases. The results showed that the use of corticosteroids in the treatment of autoimmune diseases can make diagnosis and treatment of COVID-19 more challenging by preventing the fever. Due to the common pathogenesis of COVID-19 and autoimmune diseases, the use of autoimmune drugs as a possible treatment option could help control the virus. Key Points • Inflammatory cytokines play an essential role in the pathogenesis of COVID-19 • ACE2 dysfunctions are related to the with COVID-19 and autoimmune diseases • The use autoimmune diseases drugs can be useful in treating COVID-19.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:39 |
|---|---|
| Enthalten in: |
Clinical rheumatology - 39(2020), 11 vom: 03. Sept., Seite 3223-3235 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Najafi, Sahar [VerfasserIn] |
|---|
| Links: |
Volltext [lizenzpflichtig] |
|---|
| BKL: | |
|---|---|
| Themen: |
| doi: |
10.1007/s10067-020-05376-x |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
SPR041382811 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | SPR041382811 | ||
| 003 | DE-627 | ||
| 005 | 20230520005740.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 201102s2020 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s10067-020-05376-x |2 doi | |
| 035 | |a (DE-627)SPR041382811 | ||
| 035 | |a (SPR)s10067-020-05376-x-e | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | 4 | |a 610 |q ASE |
| 082 | 0 | 4 | |a 610 |q ASE |
| 084 | |a 44.00 |2 bkl | ||
| 084 | |a 44.83 |2 bkl | ||
| 100 | 1 | |a Najafi, Sahar |e verfasserin |4 aut | |
| 245 | 1 | 4 | |a The potential similarities of COVID-19 and autoimmune disease pathogenesis and therapeutic options: new insights approach |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a Abstract Cytokine pathways and their signaling disorders can be the cause of onset and pathogenesis of many diseases such as autoimmune diseases and COVID-19 infection. Autoimmune patients may be at higher risk of developing infection due to the impaired immune responses, the use of immunosuppressive drugs, and damage to various organs. Increased secretion of inflammatory cytokines and intolerance of the patient’s immune system to COVID-19 infection are the leading causes of hospitalization of these patients. The content used in this paper has been taken from English language articles (2005–2020) retrieved from the PubMed database and Google Scholar search engine using “COVID-19,” “Autoimmune disease,” “Therapeutic,” “Pathogenesis,” and “Pathway” keywords. The emergence of COVID-19 and its association with autoimmune disorders is a major challenge in the management of these diseases. The results showed that the use of corticosteroids in the treatment of autoimmune diseases can make diagnosis and treatment of COVID-19 more challenging by preventing the fever. Due to the common pathogenesis of COVID-19 and autoimmune diseases, the use of autoimmune drugs as a possible treatment option could help control the virus. Key Points • Inflammatory cytokines play an essential role in the pathogenesis of COVID-19 • ACE2 dysfunctions are related to the with COVID-19 and autoimmune diseases • The use autoimmune diseases drugs can be useful in treating COVID-19 | ||
| 650 | 4 | |a Autoimmune disease |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a COVID-19 |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Pathogenesis |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Pathway |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Therapeutic |7 (dpeaa)DE-He213 | |
| 700 | 1 | |a Rajaei, Elham |e verfasserin |4 aut | |
| 700 | 1 | |a Moallemian, Rezvan |e verfasserin |4 aut | |
| 700 | 1 | |a Nokhostin, Forough |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Clinical rheumatology |d London : Springer, 1982 |g 39(2020), 11 vom: 03. Sept., Seite 3223-3235 |w (DE-627)SPR008480389 |w (DE-600)1480901-1 |x 1434-9949 |7 nnns |
| 773 | 1 | 8 | |g volume:39 |g year:2020 |g number:11 |g day:03 |g month:09 |g pages:3223-3235 |
| 856 | 4 | 0 | |u https://dx.doi.org/10.1007/s10067-020-05376-x |z lizenzpflichtig |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_SPRINGER | ||
| 912 | |a SSG-OLC-PHA | ||
| 936 | b | k | |a 44.00 |q ASE |
| 936 | b | k | |a 44.83 |q ASE |
| 951 | |a AR | ||
| 952 | |d 39 |j 2020 |e 11 |b 03 |c 09 |h 3223-3235 | ||